M&As this week: Stada Arzneimittel, NexImmune
German pharmaceutical company Stada Arzneimittel is intended to be fully acquired by either Cinven Partners and Advent International Corporation, which have both submitted bids.
German pharmaceutical company Stada Arzneimittel is intended to be fully acquired by either Cinven Partners and Advent International Corporation, which have both submitted bids.
"US-based biopharmaceutical company NexImmune has been fully acquired by a consortium of private investors."
Both companies that bid for the acquisition are based in the US.
US-based biopharmaceutical company NexImmune has been fully acquired by a consortium of private investors.
The acquisition will help NexImmune expand its portfolio in immuno-oncology and other immune-mediated disease areas.
The consortium, led by Celgene and CEOs of Medtronic, also includes other private investors.